Patent Grant
11529406
This application is a U.S. National Phase Application of International Application No. PCT/KR2018/000513, filed Jan. 11, 2018, which claims priority to Korean Application No. 10-2017-0024557, filed Feb. 24, 2017, each of which are hereby incorporated by reference in their entirety.
The Sequence Listing submitted Aug. 21, 2019, as a text file named “08162_0061U1_Sequence_Listing.txt,” created on Jul. 26, 2019, and having a size of 50,481 bytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e)(5).
The present invention relates to a bacteriophage isolated from nature, which infects Clostridium perfringens to thus kill Clostridium perfringens, and a method of preventing or treating a disease caused by Clostridium perfringens using a composition containing the above bacteriophage as an active ingredient. More particularly, the present invention relates to a Siphoviridae bacteriophage Clo-PEP-2 (Accession number: KCTC 13185BP) isolated from nature, which has the ability to kill Clostridium perfringens and has the genome represented by SEQ ID NO: 1, and a method of preventing or treating a disease caused by Clostridium perfringens using a composition containing the above bacteriophage as an active ingredient.
Clostridium perfringens, which is an aerophobic anaerobe (a bacterium that grows with difficulty or not at all in the presence of oxygen), is a cause of serious diseases in humans or animals such as cattle, pigs, goats and the like, and in particular is a major cause of necrotizing enterocolitis and food poisoning. The main exotoxins produced by Clostridium perfringens are present in four forms, namely α, β, ε and i. Depending on the presence or absence of these toxins, Clostridium perfringens bacteria are classified into six types from A to F. Among these, Clostridium perfringens type A is a typical cause of food poisoning and secretes only α-toxin, and Clostridium perfringens type C, which is known to cause necrotizing enteritis, secretes α-toxin and β-toxin.
Recently, the incidence of Clostridium perfringens infection has been increasing in the poultry industry, and thus has caused serious damage to farms. In particular, the damage caused by Clostridium perfringens infection in broiler chickens is very serious. Recently, the incidence of infections caused by Clostridium perfringens has also been increasing in the pig industry, and damage attributable thereto has been increasing. Therefore, it is urgent to establish methods to effectively cope with Clostridium perfringens infections.
Although various antibiotics have been used for the prevention or treatment of diseases caused by Clostridium perfringens, the incidence of bacteria resistant to these antibiotics is increasing these days, and thus the development of other methods besides antibiotics is urgent.
Recently, the use of bacteriophages as a countermeasure against infectious bacterial diseases has attracted considerable attention. In particular, these bacteriophages are receiving great attention due to strong antibacterial activity against antibiotic-resistant bacteria. Bacteriophages are very small microorganisms infecting bacteria, and are usually simply called “phages”. Once a bacteriophage infects a bacterium, the bacteriophage is proliferated inside the bacterial cell. After proliferation, the progeny of the bacteriophage destroy the bacterial cell wall and escape from the host bacteria, demonstrating that the bacteriophage has the ability to kill bacteria. The manner in which the bacteriophage infects bacteria is characterized by very high specificity thereof, and thus the range of types of bacteriophages infecting a specific bacterium is limited. That is, a certain bacteriophage may infect only a specific bacterium, suggesting that a certain bacteriophage is capable of providing an antibacterial effect only for a specific bacterium. Due to this bacterial specificity of bacteriophages, the bacteriophage confers antibacterial effects only upon target bacteria, but does not affect commensal bacteria in the environment or in the intestines of animals. Conventional antibiotics, which have been widely used for bacterial treatment, incidentally influence many other kinds of bacteria. This causes problems such as environmental pollution and the disturbance of normal flora in animals. In contrast, the use of bacteriophages does not disturb normal flora in animals, because the target bacterium is selectively killed. Hence, bacteriophages may be utilized safely, which thus greatly lessens the probability of adverse effects of use thereof compared to antibiotics.
Bacteriophages were first discovered by the English bacteriologist Twort in 1915 when he noticed that Micrococcus colonies softened and became transparent due to something unknown. In 1917, the French bacteriologist d'Herelle discovered that Shigella dysenteriae in the filtrate of dysentery patient feces was destroyed by something, and further studied this phenomenon. As a result, he independently identified bacteriophages, and named them bacteriophages, which means “eater of bacteria”. Since then, bacteriophages acting against such pathogenic bacteria as Shigella, Salmonella Typhi, and Vibrio cholerae have been continually identified.
Owing to the unique ability of bacteriophages to kill bacteria, bacteriophages have attracted attention as a potentially effective countermeasure against bacterial infection since their discovery, and a lot of research related thereto has been conducted. However, since penicillin was discovered by Fleming, studies on bacteriophages have continued only in some Eastern European countries and the former Soviet Union, because the spread of antibiotics was generalized. Since 2000, the limitations of conventional antibiotics have become apparent due to the increase in antibiotic-resistant bacteria, and the possibility of developing bacteriophages as a substitute for conventional antibiotics has been highlighted, and thus bacteriophages are again attracting attention as antibacterial agents.
As demonstrated above, bacteriophages tend to be highly specific for target bacteria. Because of the high specificity of bacteriophages to bacteria, bacteriophages frequently exhibit an antibacterial effect only for certain strains of bacteria, even within the same species. In addition, the antibacterial strength of bacteriophages may vary depending on the target bacterial strain. Therefore, it is necessary to collect many kinds of bacteriophages that are useful in order to effectively control specific bacteria. Hence, in order to develop an effective bacteriophage utilization method for controlling Clostridium perfringens, many kinds of bacteriophages that exhibit antibacterial action against Clostridium perfringens must be acquired. Furthermore, the resulting bacteriophages need to be screened as to whether or not they are superior to others in view of the aspects of antibacterial strength and spectrum.
Therefore, the present inventors endeavored to develop a composition applicable for the prevention or treatment of a disease caused by Clostridium perfringens using a bacteriophage that is isolated from nature and is capable of killing Clostridium perfringens, and further to establish a method of preventing or treating a disease caused by Clostridium perfringens using the composition. As a result, the present inventors isolated a bacteriophage suitable for this purpose from nature and determined the sequence of the genome, which distinguishes the isolated bacteriophage from other bacteriophages. Then, the present inventors developed a composition containing the bacteriophage as an active ingredient, and ascertained that this composition is capable of being used to effectively prevent or treat a disease caused by Clostridium perfringens, thus culminating in the present invention.
Accordingly, it is an object of the present invention to provide a Siphoviridae bacteriophage Clo-PEP-2 (Accession number: KCTC 13185BP) isolated from nature, which has the ability to specifically kill Clostridium perfringens and has the genome represented by SEQ ID NO: 1.
It is another object of the present invention to provide a composition applicable for preventing or treating a disease caused by Clostridium perfringens, which contains, as an active ingredient, an isolated bacteriophage Clo-PEP-2 (Accession number: KCTC 13185BP) infecting Clostridium perfringens to thus kill Clostridium perfringens.
It is another object of the present invention to provide a method of preventing or treating a disease caused by Clostridium perfringens using the composition applicable for preventing or treating a disease caused by Clostridium perfringens, which contains, as an active ingredient, the isolated bacteriophage Clo-PEP-2 (Accession number: KCTC 13185BP) infecting Clostridium perfringens to thus kill Clostridium perfringens.
It is another object of the present invention to provide a disinfectant for preventing or treating a disease caused by Clostridium perfringens using the above-described composition.
It is another object of the present invention to provide a drinking-water additive for preventing or treating a disease caused by Clostridium perfringens using the above-described composition.
It is another object of the present invention to provide a feed additive effective upon feeding by preventing or treating a disease caused by Clostridium perfringens using the above-described composition.
The present invention provides a Siphoviridae bacteriophage Clo-PEP-2 (Accession number: KCTC 13185BP) isolated from nature, which has the ability to specifically kill Clostridium perfringens and has the genome represented by SEQ ID NO: 1, and a method of preventing or treating a disease caused by Clostridium perfringens using a composition containing the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
The bacteriophage Clo-PEP-2 was isolated by the present inventors and then deposited at Korean Collection for Type Cultures, Korea Research Institute of Bioscience and Biotechnology on Jan. 11, 2017 (Accession number: KCTC 13185BP).
The present invention also provides a disinfectant, a drinking-water additive, and a feed additive applicable for the prevention or treatment of a disease caused by Clostridium perfringens, which contain the bacteriophage Clo-PEP-2 as an active ingredient.
Since the bacteriophage Clo-PEP-2 contained in the composition of the present invention kills Clostridium perfringens effectively, it is effective in the prevention (prevention of infection) or treatment (treatment of infection) of a disease caused by Clostridium perfringens. Therefore, the composition of the present invention is capable of being utilized for the prevention and treatment of a disease caused by Clostridium perfringens.
As used herein, the terms “prevention” and “prevent” refer to (i) prevention of a Clostridium perfringens infection and (ii) inhibition of the development of a disease caused by a Clostridium perfringens infection.
As used herein, the terms “treatment” and “treat” refer to all actions that (i) suppress a disease caused by Clostridium perfringens and (ii) alleviate the pathological condition of the disease caused by Clostridium perfringens.
As used herein, the terms “isolate”, “isolating”, and “isolated” refer to actions that isolate bacteriophages from nature by using diverse experimental techniques and that secure characteristics that can distinguish the bacteriophage of the present invention from others, and further include the action of proliferating the bacteriophage of the present invention using bioengineering techniques so that the bacteriophage is industrially applicable.
The pharmaceutically acceptable carrier included in the composition of the present invention is one that is generally used for the preparation of a pharmaceutical formulation, and examples thereof include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. The composition of the present invention may additionally include lubricants, wetting agents, sweeteners, flavors, emulsifiers, suspension agents, and preservatives, in addition to the above ingredients.
The bacteriophage Clo-PEP-2 is contained as an active ingredient in the composition of the present invention. The bacteriophage Clo-PEP-2 is contained at a concentration of 1×101 pfu/ml to 1×1030 pfu/ml or 1×101 pfu/g to 1×1030 pfu/g, and preferably at a concentration of 1×104 pfu/ml to 1×1015 pfu/ml or 1×104 pfu/g to 1×1015 pfu/g.
The composition of the present invention may be formulated using a pharmaceutically acceptable carrier and/or excipient in accordance with a method that may be easily carried out by those skilled in the art to which the present invention belongs, in order to prepare the same in a unit dosage form or insert the same into a multi-dose container. Here, the formulation thereof may be provided in the form of a solution, a suspension, or an emulsion in an oil or aqueous medium, or in the form of an extract, a powder, a granule, a tablet, or a capsule, and may additionally contain a dispersant or a stabilizer.
The composition of the present invention may be prepared as a disinfectant, a drinking-water additive, or a feed additive depending on the purpose of use thereof, without limitation thereto. In order to improve the effectiveness thereof, bacteriophages that confer antibacterial activity against other bacterial species may be further included in the composition of the present invention. In addition, other kinds of bacteriophages that have antibacterial activity against Clostridium perfringens may be further included in the composition of the present invention. These bacteriophages may be combined appropriately so as to maximize the antibacterial effects thereof, because their antibacterial activities against Clostridium perfringens may vary from the aspects of antibacterial strength and spectrum.
According to the present invention, the method of preventing or treating a disease caused by Clostridium perfringens using the composition containing the bacteriophage Clo-PEP-2 as an active ingredient can have the advantage of very high specificity for Clostridium perfringens, compared to conventional methods based on existing antibiotics. This means that the composition can be used for preventing or treating a disease caused by Clostridium perfringens without affecting other bacteria, namely useful commensal bacteria, and has fewer side effects attributable to the use thereof. Typically, when antibiotics are used, commensal bacteria are also damaged, ultimately lowering the immunity of animals and thus entailing various side effects owing to the use thereof. Meanwhile, in the case of various bacteriophages exhibiting antibacterial activity against the same species of bacteria, the antibacterial activities of the bacteriophages are different with regard to antibacterial strength and spectrum [the spectrum of the antibacterial activity of the bacteriophages applied to individual bacteria strains in terms of the strains of various bacteria belonging to Clostridium perfringens, bacteriophages usually being effective only on some bacterial strains, even within the same species, and the antibacterial activity of bacteriophages thus depending on the bacterial strain even for the same species of bacteria]. Accordingly, the present invention can provide antibacterial activity against Clostridium perfringens discriminating from that of other bacteriophages acting on Clostridium perfringens. This provides a great variety of effects in applicability to industrial fields.
Hereinafter, the present invention will be described in more detail with reference to Examples. However, the Examples are merely examples of the present invention, and the scope of the present invention is not limited to the Examples.
Samples were collected from nature to isolate the bacteriophage capable of killing Clostridium perfringens. Here, the Clostridium perfringens strains used for the bacteriophage isolation had been previously isolated and identified as Clostridium perfringens by the present inventors.
The procedure for isolating the bacteriophage is described in detail hereinafter. The collected sample was added to a TSB (Tryptic Soy Broth) culture medium (casein digest, 17 g/L; soybean digest, 3 g/L; dextrose, 2.5 g/L; NaCl, 5 g/L; dipotassium phosphate, 2.5 g/L) inoculated with Clostridium perfringens at a ratio of 1/1000, and then cultured at 37° C. for 3 to 4 hr under anaerobic conditions. After completion of the culture, centrifugation was performed at 8,000 rpm for 20 min and a supernatant was recovered. The recovered supernatant was inoculated with Clostridium perfringens at a ratio of 1/1000, and then cultured at 37° C. for 3 to 4 hr under anaerobic conditions. When the sample contained the bacteriophage, the above procedure was repeated a total of 5 times in order to sufficiently increase the number (titer) of bacteriophages. After repeating the procedure 5 times, the culture broth was subjected to centrifugation at 8,000 rpm for 20 min. After centrifugation, the recovered supernatant was filtered using a 0.45 μm filter. The obtained filtrate was used in a typical spot assay for examining whether or not a bacteriophage capable of killing Clostridium perfringens was included therein.
The spot assay was performed as follows: TSB culture medium was inoculated with Clostridium perfringens at a ratio of 1/1000, and then cultured at 37° C. overnight under anaerobic conditions. 3 ml (OD600 of 1.5) of the culture broth of Clostridium perfringens prepared above was spread on a TSA (Tryptic Soy Agar: casein digest, 15 g/L; soybean digest, 5 g/L; NaCl, 5 g/L; agar, 15 g/L) plate in an anaerobic incubator. The spread plate culture medium was left in the anaerobic incubator for about 30 min to thus dry the spread solution. After drying, 10 μl of the prepared filtrate was spotted onto the plate culture medium on which Clostridium perfringens was spread and then left to dry for about 30 min in the anaerobic incubator. After drying, the plate culture medium that was subjected to spotting was cultured without shaking at 37° C. for one day under anaerobic conditions, and then examined for the formation of clear zones at the positions where the filtrate was dropped. In the case in which the filtrate generated a clear zone, it was judged that the bacteriophage capable of killing Clostridium perfringens was included therein. Through the above examination, it was possible to obtain a filtrate containing the bacteriophage having the ability to kill Clostridium perfringens.
The pure bacteriophage was isolated from the filtrate confirmed above to have the bacteriophage capable of killing Clostridium perfringens. A conventional plaque assay was used to isolate the pure bacteriophage. In detail, a plaque formed in the course of the plaque assay was recovered using a sterilized tip, which was then added to the culture broth of Clostridium perfringens, followed by culturing at 37° C. for 4 to 5 hr under anaerobic conditions. After the culturing, centrifugation was performed at 8,000 rpm for 20 min to obtain a supernatant. The Clostridium perfringens culture broth was added to the obtained supernatant at a volume ratio of 1/50, followed by culturing at 37° C. for 4 to 5 hr under anaerobic conditions. In order to increase the number of bacteriophages, the above procedure was repeated at least 5 times. Then, centrifugation was performed at 8,000 rpm for 20 min in order to obtain the final supernatant. A plaque assay was further performed using the resulting supernatant. In general, the isolation of a pure bacteriophage is not completed through a single iteration of a procedure, so the above procedure was repeated using the resulting plaque formed above. After at least 5 repetitions of the procedure, the solution containing the pure bacteriophage was obtained. The procedure for isolating the pure bacteriophage was repeated in its entirety until the generated plaques became similar to each other with respect to size and morphology. In addition, final isolation of the pure bacteriophage was confirmed using electron microscopy. The above procedure was repeated until the isolation of the pure bacteriophage was confirmed using electron microscopy. The electron microscopy was performed according to a conventional method. Briefly, the solution containing the pure bacteriophage was loaded on a copper grid, followed by negative staining with 2% uranyl acetate and drying. The morphology thereof was then observed using a transmission electron microscope. The electron micrograph of the pure bacteriophage that was isolated is shown in
The solution containing the pure bacteriophage confirmed above was subjected to the following purification process. The Clostridium perfringens culture broth was added to the solution containing the pure bacteriophage at a volume ratio of 1/50 based on the total volume of the bacteriophage solution, followed by further culturing for 4 to 5 hr under anaerobic conditions. After the culturing, centrifugation was performed at 8,000 rpm for 20 min to obtain a supernatant. This procedure was repeated a total of 5 times in order to obtain a solution containing a sufficient number of bacteriophages. The supernatant obtained from the final centrifugation was filtered using a 0.45 μm filter, followed by a conventional polyethylene glycol (PEG) precipitation process. Specifically, PEG and NaCl were added to 100 ml of the filtrate reaching 10% PEG 8000/0.5 M NaCl, which was then left at 4° C. for 2 to 3 hr. Thereafter, centrifugation was performed at 8,000 rpm for 30 min to obtain the bacteriophage precipitate. The resulting bacteriophage precipitate was suspended in 5 ml of a buffer (10 mM Tris-HCl, 10 mM MgSO4, 0.1% gelatin, pH 8.0). The resulting material may be referred to as a bacteriophage suspension or bacteriophage solution.
As a result, the pure bacteriophage purified above was collected, was named the bacteriophage Clo-PEP-2, and deposited under the Budapest Treaty on the International Procedure at the Korean Collection for Type Cultures, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daijeon 305-806, Republic of Korea; the deposit was made on Jan. 11, 2017 (Accession number: KCTC 13185BP).
The genome of the bacteriophage Clo-PEP-2 was separated as follows. The genome was separated from the bacteriophage suspension obtained using the same method as in Example 1. First, in order to eliminate DNA and RNA of Clostridium perfringens included in the suspension, 200 U of each of DNase I and RNase A was added to 10 ml of the bacteriophage suspension and then left at 37° C. for 30 min. After being left for 30 min, in order to stop the DNase I and RNase A activity, 500 μl of 0.5 M ethylenediaminetetraacetic acid (EDTA) was added thereto, and the resulting mixture was then left for 10 min. In addition, the resulting mixture was further left at 65° C. for 10 min, and 100 μl of proteinase K (20 mg/ml) was then added thereto so as to break the outer wall of the bacteriophage, followed by reacting at 37° C. for 20 min. Thereafter, 500 μl of 10% sodium dodecyl sulfate (SDS) was added thereto, followed by reacting at 65° C. for 1 hr. After reaction for 1 hr, 10 ml of the solution of phenol:chloroform:isoamyl alcohol, mixed at a component ratio of 25:24:1, was added to the reaction solution, followed by mixing thoroughly. In addition, the resulting mixture was subjected to centrifugation at 13,000 rpm for 15 min to thus separate layers. Among the separated layers, the upper layer was selected, and isopropyl alcohol was added thereto at a volume ratio of 1.5, followed by centrifugation at 13,000 rpm for 10 min in order to precipitate the genome. After the precipitate was recovered, 70% ethanol was added to the precipitate, followed by centrifugation at 13,000 rpm for 10 min to wash the precipitate. The washed precipitate was recovered, vacuum-dried and then dissolved in 100 μl of water. This procedure was repeated to thus obtain a large amount of the genome of the bacteriophage Clo-PEP-2.
Information on the sequence of the genome of the bacteriophage Clo-PEP-2 obtained above was secured by performing next-generation sequencing analysis using an Illumina Mi-Seq apparatus provided by the National Instrumentation Center for Environmental Management, Seoul National University. The finally analyzed genome of the bacteriophage Clo-PEP-2 had a size of 39,456 bp, and the whole genome sequence is represented by SEQ ID NO: 1.
The homology (similarity) of the bacteriophage Clo-PEP-2 genomic sequence obtained above with previously reported bacteriophage genomic sequences was investigated using BLAST on the web. Based on the results of the BLAST investigation, the genomic sequence of the bacteriophage Clo-PEP-2 was found to have homology with the sequence of the Clostridium perfringens bacteriophage phi130 (GenBank Accession number: JF767208.1), but the identity thereof was low, namely about 69%. Also, the bacteriophage Clo-PEP-2 has an annular genome and Clostridium perfringens bacteriophage phi130 has a linear genome, and thus there is a significant difference in the genomic shape in addition to the sequence between the genomes of these two bacteriophages. Furthermore, the number of open reading frames (ORFs) on the bacteriophage Clo-PEP-2 genome is 64, whereas the Clostridium perfringens bacteriophage phi130 has 55 open reading frames, from which these two bacteriophages are also evaluated to be different.
Therefore, it can be concluded that the bacteriophage Clo-PEP-2 is a novel bacteriophage different from conventionally reported bacteriophages. Moreover, since the antibacterial strength and spectrum of bacteriophages typically depend on the type of bacteriophage, it is considered that the bacteriophage Clo-PEP-2 can provide antibacterial activity different from that of any other bacteriophages reported previously.
The killing ability of the isolated bacteriophage Clo-PEP-2 for Clostridium perfringens was investigated. In order to evaluate the killing ability, the formation of clear zones was observed using a spot assay in the same manner as described in connection with Example 1. A total of 10 strains that had been isolated and identified as Clostridium perfringens by the present inventors were used as Clostridium perfringens for the investigation of killing ability. The bacteriophage Clo-PEP-2 had the ability to kill a total of 9 strains, among 10 strains of Clostridium perfringens, that is, the experimental target. The representative experimental results thereof are shown in
Therefore, it can be concluded that the bacteriophage Clo-PEP-2 has high ability to kill Clostridium perfringens and an antibacterial effect against many Clostridium perfringens strains, indicating that the bacteriophage Clo-PEP-2 can be used as an active ingredient of the composition for preventing or treating diseases caused by Clostridium perfringens.
100 μl of a bacteriophage Clo-PEP-2 solution at a level of 1×108 pfu/ml was added to a tube containing 9 ml of a TSB culture medium. To another tube containing 9 ml of a TSB culture medium, only the same amount of TSB culture medium was further added. A Clostridium perfringens culture broth was then added to each tube under anaerobic conditions so that absorbance reached about 0.5 at 600 nm. After addition of Clostridium perfringens, the tubes were cultured at 37° C. under anaerobic conditions, during which the growth of Clostridium perfringens was observed. As shown in Table 1 below, it was observed that the growth of Clostridium perfringens was inhibited in the tube to which the bacteriophage Clo-PEP-2 solution was added, whereas the growth of Clostridium perfringens was not inhibited in the tube to which the bacteriophage solution was not added.
The above results show that the bacteriophage Clo-PEP-2 of the present invention not only inhibits the growth of Clostridium perfringens but also has the ability to kill Clostridium perfringens. Therefore, it is concluded that the bacteriophage Clo-PEP-2 can be used as an active ingredient of the composition for preventing diseases caused by Clostridium perfringens.
The preventive effect of the bacteriophage Clo-PEP-2 on diseases caused by Clostridium perfringens was evaluated using weaning pigs. 20 of 25-day-old weaning pigs were divided into a total of 2 groups of 10 pigs per group and reared separately in experimental pig-rearing rooms (1.1 m×1.0 m), and the test was performed for 14 days. The surrounding environment was controlled using a heater, and the temperature and humidity in the pig rooms were maintained constant, and the pig room floors were washed every day. A feed containing 1×108 pfu/g of bacteriophage Clo-PEP-2 was supplied to pigs in the experimental group (administered with feed containing the bacteriophage) in a typical feeding manner starting from the test until the end of the test. In contrast, a feed having the same composition but excluding bacteriophage Clo-PEP-2 was supplied to pigs in the control group (administered with feed not containing the bacteriophage) in the same feeding manner starting from the test until the end of the test. For 2 days from the seventh day after the start of the test, the feed was further added with 1×108 pfu/g of Clostridium perfringens and then supplied to all of the pigs in the experimental group (administered with feed containing the bacteriophage) and the control group (administered with feed not containing the bacteriophage) twice a day, thereby inducing infection with Clostridium perfringens. The detected level of Clostridium perfringens in the feces of all test animals was examined daily from the date of the feeding with the feed containing Clostridium perfringens (from the seventh day after the start of the test), and the extent of diarrhea of the pigs was also examined.
The detection of Clostridium perfringens in feces was carried out as follows. The fecal sample was spread on a Clostridium-perfringens-selective medium (a TSC agar plate; OXOID) and then cultured at 37° C. for 18 to 24 hr under anaerobic conditions. Among the resulting colonies, colonies presumed to be Clostridium perfringens were isolated. The colonies thus obtained were used as samples and subjected to polymerase chain reaction (PCR) specific to Clostridium perfringens, and thus whether or not the corresponding colonies were Clostridium perfringens was finally confirmed.
The extent of diarrhea was determined by measuring according to a diarrhea index. The diarrhea index was measured using a commonly used Fecal Consistency (FC) score (normal: 0, soft stool: 1, loose diarrhea: 2, severe diarrhea: 3).
The results are shown in Tables 2 and 3 below.
Clostridium perfringens
As is apparent from the above results, it can be concluded that the bacteriophage Clo-PEP-2 of the present invention is very effective in the prevention of diseases caused by Clostridium perfringens.
The therapeutic effect of the bacteriophage Clo-PEP-2 on diseases caused by Clostridium perfringens was evaluated as follows. 2 groups of forty 2-day-old chicks per group were prepared and reared separately, and the test was performed for 14 days. For 3 days from the fifth day after the start of the test, a feed containing 1×107 cfu/g of Clostridium perfringens was supplied in a typical feeding manner. From the last day of feeding with feed containing Clostridium perfringens, Clostridium perfringens was found in the feces of both groups. From the next day (the eighth day after the start of the test) after the feeding with the feed containing Clostridium perfringens for 3 days, a feed containing 1×108 pfu/g of bacteriophage Clo-PEP-2 was supplied to chicks in the experimental group (administered with feed containing the bacteriophage) in a typical feeding manner. In contrast, a feed having the same composition but excluding bacteriophage Clo-PEP-2 was supplied to chicks in the control group (administered with feed not containing the bacteriophage) in the same manner. From the ninth day after the start of the test, the number of Clostridium perfringens bacteria in the feces of the test animals was measured. A Clostridium-perfringens-selective medium (a TSC agar plate) was used to prevent interference with other contaminating bacteria in the measurement of the number of Clostridium perfringens bacteria in this example. The sample was spread on the selective medium under anaerobic conditions and then cultured at 37° C. for 18 to 24 hr under anaerobic conditions. Colonies presumed to be Clostridium perfringens were isolated from the selective medium, after which Clostridium perfringens was identified through polymerase chain reaction (PCR) (the case where the number of colonies identified as Clostridium perfringens through PCR is 102 cfu/ml or more=2, the case where the number of colonies identified as Clostridium perfringens through PCR is 101˜102 cfu/ml=1, and the case where the number of colonies identified as Clostridium perfringens through PCR is 10°˜101 cfu/ml=0). The results are shown in Table 4 below.
perfringens bacteria (mean)
As is apparent from the above results, it can be concluded that the bacteriophage Clo-PEP-2 of the present invention is very effective in the treatment of diseases caused by Clostridium perfringens.
A feed additive was prepared using a bacteriophage Clo-PEP-2 solution so that a bacteriophage Clo-PEP-2 was contained in an amount of 1×109 pfu for 1 g of the feed additive. The method of preparing the feed additive was as follows: Maltodextrin (50%, w/v) was added to the bacteriophage solution, and the resulting mixture was then freeze-dried. Finally, the dried mixture was ground into fine powder. In the above-described preparation procedure, the drying process may be replaced with drying under reduced pressure, drying with heat, or drying at room temperature. In order to prepare the control for comparison, the feed additive that did not contain the bacteriophage but contained a buffer (10 mM Tris-HCl, 10 mM MgSO4, 0.1% gelatin, pH 8.0) used to prepare the bacteriophage solution was prepared.
The two kinds of feed additives thus prepared were each mixed with a poultry-based feed at a weight ratio of 1,000, thus ultimately preparing two kinds of feed.
A drinking-water additive and a disinfectant were prepared in the same manner because they differ only in utilization and are the same in dosage form. The drinking-water additive (or disinfectant) was prepared using a bacteriophage Clo-PEP-2 solution so that a bacteriophage Clo-PEP-2 was contained in an amount of 1×109 pfu for 1 ml of the drinking-water additive (or disinfectant). In the method of preparing the drinking-water additive (or disinfectant), the bacteriophage Clo-PEP-2 solution was added so that the bacteriophage Clo-PEP-2 was contained in an amount of 1×109 pfu for 1 ml of the buffer used to prepare the bacteriophage solution, and mixing was sufficiently performed. In order to prepare the control for comparison, the buffer used to prepare the bacteriophage solution was used without change as the drinking-water additive (or disinfectant) that did not contain the bacteriophage.
The two prepared kinds of drinking-water additives (or disinfectants) were diluted with water at a volume ratio of 1,000, thus ultimately preparing drinking water or disinfectants.
An improvement in chicken farming as the result of feeding was investigated using the feed, drinking water or disinfectant prepared in Examples 7 and 8. In particular, the investigation was focused on mortality. 120 of 2-day-old chicks were divided into three groups, each including 40 chicks (group A: fed with the feed, group B: fed with the drinking water, and group C: treated with the disinfectant), and the test was performed for four weeks. Each group was divided into subgroups each including 20 chicks, and the subgroups were classified into a subgroup to which the bacteriophage Clo-PEP-2 was applied (subgroup-{circle around (1)}) and a subgroup to which the bacteriophage was not applied (subgroup-{circle around (2)}). In the present test, the chicks were raised separately in individual subgroups. The subgroups were classified and named as shown in Table 5 below.
In the case of provision of the feed, the feed prepared in Example 7 was provided according to a typical feeding method as classified in Table 5, and the drinking water prepared in Example 8 was provided according to a typical drinking-water provision method as classified in Table 5. In the case of disinfection, the disinfection was carried out alternately with existing disinfection 3 times a week. Disinfection using a typical disinfectant was not performed on the day on which the disinfectant of the present invention was sprayed. The test results are shown in Table 6 below.
The above results indicate that the provision of the feed and the drinking water prepared according to the present invention and the disinfection according to the present invention were effective in reducing mortality upon chicken farming. Therefore, it is concluded that the composition of the present invention is capable of being effectively applied to improving the results of chicken feeding.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, those skilled in the art will appreciate that the specific description is only a preferred embodiment, and that the scope of the present invention is not limited thereto. It is therefore intended that the scope of the present invention be defined by the claims appended hereto and their equivalents.
[Accession Number]
Name of Depositary Authority: KCTC
Accession number: KCTC 13185BP
Accession date: 20170111
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2017-0024557 | Feb 2017 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2018/000513 | 1/11/2018 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2018/155814 | 8/30/2018 | WO | A |
| Number | Date | Country |
|---|---|---|
| 20120076710 | Jul 2012 | KR |
| 101381798 | Apr 2014 | KR |
| 20160013243 | Feb 2016 | KR |
| 20160080175 | Jul 2016 | KR |
| WO-2018155814 | Aug 2018 | WO |
| Entry |
|---|
| PCT, PCT/KR2018/000513 (WO 2018/155814), Jan. 11, 2018 (Aug. 30, 2018), Intron Biotechnology, Inc. |
| Oakley, et al., “Comparative genomics of four closely related Clostridium perfringens bacteriophages reveals variable evolution among core genes with therapeutic potential”, BMC Genomics 2011, 12:282. |
| International Search Report and Written Opinion dated Apr. 24, 2018 by the International Searching Authority for International Application No. PCT/KR2018/000513, filed on Jan. 11, 2018 and published as WO 2018/155814 on Aug. 30, 2018 (Applicant—Intron Biotechnology, Inc.) (Original—8 Pages / Translation—2 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20200054042 A1 | Feb 2020 | US |
